Monday, 29 April, 2024
HomeNews UpdateSAHPRA issues warning about fake Ozempic

SAHPRA issues warning about fake Ozempic

The South African Health Products Regulatory Authority (SAHPRA) has said it is aware of fake Ozempic products being sold on the market and online, and warned the public to beware of these unauthorised Ozempic/semaglutide-containing products that are being disseminated through radio stations and social media platforms.

It said it has not authorised/registered Ozempic for weight-loss, so use in that regard would be off-label – and additionally, only a healthcare practitioner can make a Schedule 4 product available off-label.

Novo Nordisk SA has confirmed a national shortage of Ozempic stock, resulting in limited access to treatment for diabetic patients, which, said SAHPRA, might have created an opportunity for falsified/counterfeit products to flood the market.

Currently, no generic versions of this medicine are being lawfully manufactured.

 

See more from MedicalBrief archives:

 

Fake Ozempic sends users to hospitals

 

Warning about fake weight loss medication pens

 

Belgium wants temporary Ozempic ban

 

SA stocks of diabetes drug drained after global weight loss frenzy

 

 

 

 

 

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.